|
Dr. Smith joined Novavax with more than 15 years experience in the development of human and veterinary vaccines therapeutics and diagnostics. Prior to coming to Novavax Dr. Smith was with Protein Sciences Corporation as the company's Chief Scientific Officer. Dr. Smith also led the scientific team that developed the first experimental vaccine for Human Immunodeficiency Virus (HIV) approved by the FDA for testing in the U.S. He was also responsible for a broad range of discovery efforts including vaccines for viral Influenza malaria cancer and improved methods for manufacturing biopharmaceuticals. In 1997 Dr. Smith responded to an emergency request from the NIH to produce several thousand doses of an experimental vaccine against H5N1 avian influenza that had jumped from birds to man in Hong Kong.
As a recognized authority on vaccines and insect cell technology Dr. Smith has co-authored numerous articles in Science Virology Vaccine Journal of Infectious Disease and the New England Journal of Medicine. He also holds various patents in the area of vaccine technology and is the senior inventor of the insect cell baculovirus expression technology which is widely used in the discovery and manufacture of recombinant DNA products including human vaccines.
Prior to joining Protein Sciences he was a Faculty Research Scientist at Texas A & M University.
Education
1983 Ph.D. in Microbiology Texas A & M University and Baylor College of Medicine
1974 B.S. in Biology/Chemistry University of North Dakota
| 